NEW YORK, January 24, 2017 /PRNewswire/ --
Stock-Callers.com today has issued research reports on four equities which are: Zoetis Inc. (NYSE: ZTS), Mallinckrodt PLC (NYSE: MNK), Akorn Inc. (NASDAQ: AKRX), and Diplomat Pharmacy Inc. (NYSE: DPLO). According to pharmaceutical manufacturer PCI Synthesis, there is a potential for significant change in 2017 for the Generic Drugs industry, including a possible reduction in FDA red tape, tighter capacity because of the industry's current growth, and a speedier FDA approval process that could reduce its backlog by the end of next year. However, significant uncertainty is also expected due to the new administration. Download the free research reports on these stocks today:
Florham Park, New Jersey headquartered Zoetis Inc.'s shares saw a slight decline of 0.41%, finishing Monday's trading session at $53.75. A total volume of 2.98 million shares was traded. The stock has advanced 1.42% in the past month, 5.19% in the previous three months, and 0.61% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 4.01% and 8.14% respectively. Moreover, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have a Relative Strength Index (RSI) of 60.01.
On December 30th, 2016, Zoetis announced that it will host a webcast and conference call at 8:30 a.m. ET on February 16th, 2017. CEO Juan Ramón Alaix and Executive Vice President and CFO Glenn David will review Q4 2016 and FY16 financial results and respond to questions from financial analysts during the call. See our free and comprehensive research report on ZTS at:
On Monday, shares in Chesterfield, the UK-based Mallinckrodt PLC recorded a trading volume of 1.48 million shares, and ended the session 0.95% lower at $45.64. The stock is trading 15.74% below its 50-day moving average. Shares of the Company, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, the Middle East, Africa, and internationally, have an RSI of 32.96.
On January 18th, 2017, Mallinckrodt announced that it has reached agreement with the US Federal Trade Commission (FTC) to resolve, without admission of wrongdoing, the previously disclosed FTC's investigation into the acquisition by Questcor Pharmaceuticals, Inc., of Synacthen® Depot, a synthetic ACTH product, in 2013. The product became part of Mallinckrodt's portfolio with its August 2014 acquisition of Questcor. Under the agreement, Mallinckrodt will license the drug to a licensee, identified by the FTC as Marathon Pharmaceuticals, LLC, to develop and pursue possible US Food and Drug Administration (FDA) approval of Synacthen Depot in two indications - Infantile Spasms and Nephrotic Syndrome. The licensee will also acquire exclusive rights to the Synacthen trademark in the US. Under the agreement, Mallinckrodt will also pay $100 million to settle claims made by the FTC and five states - $90 million of which will be paid within 10 business days, $10 million within 90 days - plus $2 million to reimburse the states' legal fees. MNK free research report PDF is just a click away at:
Shares in Lake Forest, Illinois headquartered Akorn Inc. closed at $20.17, down 1.71% from the last trading session. The stock recorded a trading volume of 1.04 million shares. The Company's shares are trading 5.41% below their 50-day moving average. Additionally, shares of Akorn, which develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter consumer health products and animal health pharmaceuticals in the US and internationally, have an RSI of 38.29.
On December 12th, 2016, Akorn announced that the US FDA conducted a re-inspection of its Decatur, Illinois manufacturing facility from December 05th, 2016 to December 09th, 2016, with no Form 483 observations. The re-inspection was conducted to verify the implementation and effectiveness of Akorn's responses to the observations from the June 2016 FDA's inspection. Sign up for your complimentary report on AKRX at:
At the closing bell yesterday, shares in Flint, Michigan headquartered Diplomat Pharmacy Inc. ended 2.96% lower at $13.11 with a total trading volume of 1.29 million shares. The stock has advanced 4.05% on an YTD basis. The Company's shares are trading below their 50-day moving average by 4.60%. Furthermore, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have an RSI of 46.25.
On January 09th, 2017, Diplomat announced that it has signed a definitive agreement to acquire Affinity Biotech, Inc. Under terms of the agreement, Diplomat will purchase Affinity Biotech for $16 million cash, and up to an additional $4 million in contingent consideration. The closing of the transaction is expected to occur in February 2017. Register for free on Stock-Callers.com and download the latest research report on DPLO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA